CALL US:022-2204 0015 / 16 / 17   isa@saffronmedia.in
HOME NEWS INGREDIENT MART EVENTS TOPICS INTERVIEW EDIT
 
News
 
Irvine, California May 31 , 2019
Aivita Biomedical, a privately held company engaged in the advancement of commercial and clinical-stage programs utilizing curative and regenerative medicines, has announced the execution of a deal with custom formulator and beauty product developer Lacore Laboratories.

The deal allows for the use of Aivita’s proprietary actives complex in a new line of skincare products to be distributed by Lacore’s subsidiary Generation New Online across greater Asian countries. Consumers in Hong Kong, Taiwan, Singapore, Malaysia and Mainland China will be among the first to have access to the new line.

Aivita’s proprietary active technology is a science-based multi-functional ingredient complex and delivery system which captures the natural cell messaging system and ingredients of skin stem cells. The active contains a complete and balanced mix of all the naturally-occurring, revitalizing factors present in a young skin environment.

“Lacore brings unique capabilities to Aivita, including their cultural knowledge of product preferences and their distribution prowess throughout Asia”, said Dr. Hans Keirstead, chairman and chief executive officer of Aivita Biomedical, “We’re thrilled to be bringing our revolutionary active technology to consumers throughout the world”.

Share This Story

Leave a Reply
Your name (required)   Your email (required)
         
Website (required)
   
CommenT
 
Enter Code (Required)

 

 

 
INGREDIENT MART

RECENT NEWS

TOPICS
India needs to align with global good practices to reinvogorate its capability in pharmaceutical manufacture. The regula ...

 

MAIN LINKS OUR SERVICES OTHER PRODUCTS ONLINE MEDIA  
 
About Us
Contact Us
News Archives
 

Product Finder
Features and Articles
News
 
Chronicle Pharmabiz
Food & Bevergae News
Ingredients South Asia
 
Media Information
Rate Card
Advertise
 
 
Copyright © 2013 Saffron Media Pvt Ltd. All Rights Reserved.
Best View in Internet Explorer(9.0) or Firefox(26.0)